Related Experiment Video
Updated: Sep 18, 2025
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Design, synthesis, and evaluation of 1,3,4-oxadiazole-based EGFR inhibitors
Zijun Tang1, Mingxing Hu2, Ye Gan3
1Guangxi Key Laboratory of Special Biomedicine; School of Medicine, Guangxi University, Nanning, 530004, PR China; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, 610041, PR China.
Abstract:
The epidermal growth factor receptor (EGFR), a member of the receptor tyrosine kinase (RTK) family, serves as a validated and significant therapeutic target in various cancers. EGFR inhibitors have substantially improved the treatment outcomes for patients with EGFR-positive tumors. The EGFRT790M mutation has emerged as a leading cause of clinically acquired resistance to both first- and second-generation EGFR inhibitors. In this study, we integrated azoles, particularly 1,3,4-oxadiazoles, into a preferred quinazoline scaffold to design novel EGFR inhibitors. Compound 4b, a new 1,3,4-oxadiazole-based EGFR inhibitor, demonstrated superior potency against the EGFRL858R/T790M mutant (IC50 = 17.18 nM compared to 733.20 nM for Erlotinib) and in NCI-H1975 cells (IC50 = 2.17 ± 0.20 μM compared to 11.01 ± 0.05 μM for Erlotinib). Furthermore, 4b significantly inhibited the migration of both A431 and NCI-H1975 cells and induced G1 phase cell cycle arrest in NCI-H1975 cells. In conclusion, these findings suggest that 4b is a promising lead compound for the development of inhibitors targeting the EGFRL858R/T790M mutation.
Insights
A novel 1,3,4-oxadiazole-based compound, 4b, shows potent inhibition against the EGFR T790M mutation, a key resistance mechanism. This compound effectively targets EGFR-resistant cancers and inhibits cell migration and induces cell cycle arrest.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFR) is a crucial target in cancer therapy.
- Acquired resistance to EGFR inhibitors, particularly the T790M mutation, poses a significant clinical challenge.
- Novel therapeutic strategies are needed to overcome resistance in EGFR-mutated cancers.
Purpose of the Study:
- To design and synthesize novel EGFR inhibitors incorporating 1,3,4-oxadiazole moieties.
- To evaluate the efficacy of these compounds against EGFR mutations, especially T790M.
- To investigate the anti-cancer effects of the lead compound, 4b.
Main Methods:
- Integration of 1,3,4-oxadiazoles into a quinazoline scaffold to create new EGFR inhibitors.
- In vitro biochemical assays to determine inhibitory concentrations (IC50) against EGFR mutants.
- Cell-based assays to assess effects on cell migration and cell cycle progression.
Main Results:
- Compound 4b exhibited superior potency against the EGFR L858R/T790M mutant compared to Erlotinib.
- 4b demonstrated significant inhibition of cell migration in A431 and NCI-H1975 cells.
- Treatment with 4b induced G1 phase cell cycle arrest in NCI-H1975 cells.
Conclusions:
- Compound 4b is a potent EGFR inhibitor targeting the T790M resistance mutation.
- 4b displays promising anti-migratory and cell cycle-disrupting properties.
- 4b represents a potential lead compound for developing new therapies against EGFR-resistant lung cancer.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
02:38Mitogens and the Cell Cycle
01:26Drug Discovery: Overview